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A B S T R A C T
Purpose: In this Argentinean retrospective, collaborative, multicenter study, we examine the efﬁcacy and
tolerability of the ketogenic diet (KD) for different epilepsy syndromes.
Materials and methods: we evaluated the clinical records of 216 patients started on the KD between
March 1, 1990 and December 31, 2010.
Results: One hundred forty of the initial patients (65%) remained on the diet at the end of the study
period. Twenty-nine patients (20.5%) became seizure free and 50 children (36%) had a 75–99% decrease
in seizures. Thus, 56.5% of the patients had a seizure control of more than 75%. The best results were
found in patients with epilepsy with myoclonic-astatic seizures, Lennox–Gastaut syndrome, and West
syndrome. Good results were also found in patients with Dravet syndrome, in those with symptomatic
focal epilepsy secondary to malformations of cortical development, and in patients with tuberous
sclerosis. Seizures were signiﬁcantly reduced in four patients with fever-induced refractory epileptic
encephalopathy in school-age children and in two patients with epileptic encephalopathy with
continuous spikes and waves during slow sleep. The median period of follow-up after discontinuation of
the diet was 6 years. Twenty patients who had become seizure free discontinued the diet, but seizures
recurred in ﬁve (25%). Of 40 patients with a seizure reduction of more than 50% who discontinued the
diet, 10 presented with recurrent seizures.
Conclusion: The ketogenic diet is a good option in the treatment of refractory epilepsy. After
discontinuing the diet, seizures recurrence occurred in few patients.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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The ketogenic diet (KD) is a high-fat, low-carbohydrate,
adequate-protein diet. It is an established, effective, non-pharma-
cologic treatment that has been used as an alternative in the
management of refractory epilepsy.1–9 The KD is now considered a
safe and effective optional therapy not only for children but also for
adults with intractable epilepsy.10,11
Recently, modiﬁcations of the original KD, such as the Atkins
diet and a low-glycemic-index diet, have been developed as
alternatives for the treatment of refractory epilepsy.10–13 However,
these diets may not be as effective as the KD.* Corresponding author at: Neurologı´a, Hospital Nacional de Pediatrı´a ‘‘Prof Dr
Juan P. Garrahan’’, Combate de los Pozos 1881, Buenos Aires CP 1245, Argentina.
Tel.: +54 114943 6116; fax: +54 114943 6116.
E-mail address: rhcaraballo@arnet.com.ar (R. Caraballo).
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.06.009Although a large number of patient series has been reported, only
a small number of controlled studies have been undertaken.1,14–16 A
recent randomized controlled trial supports its use in children with
refractory epilepsy.8 In this trial, 28 of the diet group had a greater
than 50% seizure reduction compared with four controls (6%), and
ﬁve children (7%) in the diet group had a greater than 90% seizure
reduction compared with none of the controls.8 A randomized trial
of classic and medium-chain triglyceride ketogenic diets in the
treatment of childhood epilepsy has revealed that both diets are
comparable in efﬁcacy and tolerability; both ways of implementing
the diet proved useful in the treatment of childhood epilepsy.8
Eighty-one percent of the members of a recent international
consensus group on the KD believed that the classic diet
should be offered to a child after two anticonvulsants have been
used unsuccessfully, excluding surgically remediable epileptic
syndromes.9
Several investigators have suggested that the diet might be
beneﬁcial for seizure control in speciﬁc epileptic syndromes, andvier Ltd. All rights reserved.
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speciﬁc disorders.11,30
A wide range of hypotheses has been suggested to explain
the efﬁcacy of the KD.31,32 It is clear that fasting and the KD
share a common mechanism in controlling seizures. The brain
is an obligate user of glucose as its energy source. When
carbohydrates are restricted, as in the KD or fasting, the brain no
longer uses only glucose and starts to oxidize ketone bodies
derived from fats instead of carbohydrates as the primary fuel
source.31
In this Argentinean retrospective, collaborative, multicenter
study, we examine the efﬁcacy and tolerability of the KD in
different epilepsy syndromes.
2. Materials and methods
We evaluated the clinical records of 216 patients started on the
KD between March 1, 1990 and December 31, 2010.
The epileptic syndromes were deﬁned according to the ILAE
classiﬁcation (Engel, 2001, 2006). These patients were seen at the
department of neurology in three Argentinean centers between
February 1990 and December 2009. One hundred thirty-six were
seen at the Garrahan Hospital of Buenos Aires, 46 patients were
seen at the Italian Hospital of Buenos Aires, and 34 were seen at
the Centro de Neurociencias del Litoral, Santa Fe´. Some of these
patients were included in previous publications.4,20–23,33 We
used the Johns Hopkins Hospital Protocol diet in all patients.
During diet initiation, blood glucose, urine ketones, and vital
signs were routinely checked. The efﬁcacy and tolerability of the
diet was controlled every three months in the ﬁrst year, and
every six months in the follow years. Seizure frequency was
registered three months before starting the diet, and at
subsequent control visits on the basis of daily seizure calendars
kept by the parents.
We analyzed gender, age at onset of seizures, seizure
semeiology, family and personal history, physical examination,
clinical evolution, and treatment. Brain CT scan and MRI were
performed in all patients. Neurometabolic tests were done in 89
patients, and karyotype studies were performed in 68 patients. In
addition to a complete examination, including growth parameters
such as weight and height, laboratory studies were performed. All
patients had several awake and sleep EEGs studies, and back-
ground activity, topography, and morphology of the paroxysms
were analyzed. The EEG electrodes were placed according to the
international 10–20 system. Video-EEG studies were done in most
of the patients. Neuropsychological tests (Bayley, Vineland,
Terman-Merryl, or WISC) to evaluate IQ were systematically
administered to all patients. We also evaluated the duration of the
diet, the reason why the diet was discontinued, and outcome after
discontinuation the diet.
We considered the following inclusion and exclusion criteria:
- Inclusion criteria
1. Patients with refractory epilepsy after two or three antic-
onvulsants were used unsuccessfully.
2. Age between 1 and 18 years were included.
- Exclusion criteria
1. Patients with liver, kidney, heart, gastrointestinal, psychiatric
diseases, and progressive encephalopathy with or without a
known metabolic marker, except those metabolic diseases for
which the KD is the speciﬁc treatment.
2. Inability to maintain adequate nutrition, and parent or
caregiver noncompliance.
Patients are reported as-seizure free in this study if they have
remained free of seizures during all period of this study.3. Results
3.1. General characteristics
Two hundred sixteen patients (119 males, 97 females) were
followed for 1–20 years. Mean age at onset of the diet was 5 years
(range, 1–18 years). Mean duration of the diet treatment was 3.5
(range, 1–12 years). The mean time of follow-up was 9 years
(range, 1–20 years).
The children had previously received a mean of six different
AEDs and were on a mean of 3.5 AEDs when the diet was begun.
Eighteen months after initiating the diet, 140 of the initial
patients (65%) remained on the diet. Thirty-one patients (22%)
were seizure free, 48 children (34.5%) had a 75–99% decrease in
seizures, 14 children (10%) had a 50–74% decrease in seizures, and
the remaining 47 patients (33.5%) had less than 50% decrease in
seizures. Thus, 18 months after starting the diet, seventy-nine of
the initial patients (56.5%) had achieved a more than 75% decrease
in their seizures. There were no apparent differences in efﬁcacy
based on age or sex.
Seventy-six of the 216 children (35%) who initiated the diet
discontinued within the ﬁrst year. In 43, the reason given for
discontinuing the diet was lack of effectiveness. Thirty of these
children discontinued between 1 and 2 months and 13 discon-
tinued 3 months after starting the diet. In 21 patients persistent
and severe vomiting and hypoglycemia were the reason for
discontinuing the diet one month after initiation. Twelve patients
were not able to maintain the diet accordingly.
Fifty patients remained on the diet for more than three years,
seventy patients for 2–3 years, and 20 patients for 1–2 years.
3.2. Electroencephalographic changes
In all 140 patients who followed the KD, the EEG recordings
carried out at least 3 months before starting KD showed
generalized and/or focal epileptiform discharges. Eighteen months
after initiating the diet, the EEG abnormalities had improved in
most of the patients who had achieved a more than 75% decrease in
their seizures. The EEG recording became normal in 29 patients
who had become seizure free. In two patients who had become
seizure free and in 40 patients who achieved a 75–99% seizure
reduction, the EEG abnormalities improved between 50% and 70%.
In 14 patients who achieved a 50–74% decrease in their seizures,
the EEG abnormalities improved between 25 and 50%. The EEG
abnormalities remained unchanged in 47 patients in whom seizure
control improved less than 50%.
3.3. Decreasing and discontinuing medications
Medications were decreased and discontinued non-systemati-
cally with the aim of the patient becoming medication free.
Medications were discontinued in 40 patients and signiﬁcantly
decreased in 53 patients.
3.4. Efﬁcacy in different epilepsy syndromes
The types of epilepsy or epileptic syndrome and etiologies in
212 patients with refractory epilepsy treated with the KD are
shown in Table 1.
The remaining patients included in our series of patients were:
two patients with GLUT-1 deﬁciency, one of whom had epileptic
encephalopathy and the other refractory epilepsy with typical
absences, one patient with Rett syndrome associated with
myoclonic status, and another with subacute sclerosing panence-
phalitis associated with epileptic spasms in clusters and focal
seizures with or without secondary generalization.
Table 1
Types of epilepsy or epileptic syndrome found in 212 patients with refractory epilepsy treated with the KD.
Type of epilepsy and epileptic syndrome Etiology Number of patients
Symptomatic focal epilepsy Cortical dysplasia 20
Tuberous sclerosis 13
Encephalitis 18
Hypoxic–ischemic encephalopathy 11
Porencephalic cyst 3
Vascular malformations 4
Epilepsy with myoclonic-astatic seizures 38
Cryptogenic Lennox–Gastaut syndrome 7
Symptomatic Lennox–Gastaut syndrome Encephalitis 6
Cortical dysplasia 10
Chromosomal abnormalities 4
Neonatal hypoglycemia 3
Hypoxic–ischemic encephalopathy 2
Cryptogenic West syndrome 8
Symptomatic West syndrome Hypoxic–ischemic encephalopathy 4
Porencephalic cyst 4
Cortical dysplasia 5
Aicardi syndrome 2
Tuberous sclerosis complex 2
Septo-optic dysplasia 1
Meningitis 1
Encephalitis 1
Dravet syndrome 32
Cryptogenic epileptic encephalopathy with CSWSS 3
Symptomatic epileptic encephalopathy with CSWSS Unilateral polymicrogyria 2
Fever-induced refractory epileptic encephalopathy 5
Epilepsy with myoclonic absences 2
Migrating focal seizures in infancy 1
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in Table 2. Both patients with GLUT-1 deﬁciency became seizure
free. One patient with Rett syndrome and myoclonic status and
another patient with subacute sclerosing panencephalitis associ-
ated with epileptic spasms had a seizure reduction between 75%
and 99%
3.5. Therapy
Different antiepileptic drugs treatment schemes were used
associated with the KD. It is of interest that ten patients who
became seizure free, ﬁfteen patients with a 75–99% seizure
reduction, and three patients with a 50–74% seizure reduction
received topiramate.
3.6. Side-effects
Table 3 lists the adverse effects of the KD in 140 patients who
remained on the diet. Side effects were well treatable. Three of six
patients who developed kidney stones had received topiramate.
The same table also shows the more severe adverse events
provoked by discontinuation of the diet. Five patients died during
the treatment with the KD. Cause of death was pneumonia in two,Table 2
Efﬁcacy of the ketogenic diet considering the epileptic syndromes in 136 patients.
Epileptic syndrome Seizure freedom
(N of patients)
75–99% seiz
(N of patien
Symptomatic focal epilepsy 2 17 
Epilepsy with myoclonic-astatic seizures 11 9 
Dravet syndrome 2 10 
West syndrome 5 2 
Lennox–Gastaut syndrome 7 4 
FIRES 1 2 
CSWSS 1 1 
Epilepsy with myoclonic absences – 1 
Migrating focal seizures in infancy – – sepsis in one, status epilepticus in one, and was unknown in the
remaining patient.
3.7. Evolution
The diet was discontinued for the following reasons: seizure
freedom for more than 2 years in 20 (14%), seizure reduction of
more than 50% for more than two years in 40 (28%), severe
toxicities in seven (5%), inability to adhere to the diet in 14 (10%),
lack of efﬁcacy in 12 patients (8%), and patient or family request in
12 patients (8%).
3.8. Outcome after discontinuation of the diet
The median period of follow-up after discontinuation of the diet
was 6 years (range, 1–15 years). Seizures recurred in ﬁve (25%) of
20 patients in the seizure free group who discontinued the diet. Of
40 patients with a seizure reduction of more than 50% who
discontinued the diet, seizure frequency remained the same in 30,
seizures recurred in 10, and seizure frequency decreased in ﬁve. All
patients in the seizure free group and those in the group with a
seizure reduction of more than 50% in whom seizures recurred
after diet discontinuation had brain lesions and EEG abnormalities.ure reduction
ts)
50–74% seizure reduction
(N of patients)
Less than 50% seizure
reduction (N of patients)
5 24
1 4
4 4
2 3
1 7
1 1
– 2
– 1
– 1
Table 3
Side effects of the ketogenic diet in 174 (80.5%) patients.
Adverse events Number of
patients
Diet
discontinuation
Vomiting 15 No
Diarrhea 12 No
Anorexia 8 No
Constipation 18 No
Abdominal pain 13 No
Weight gain 5 No
Hypercholesterolemia 10 No
Hypertriglycerinemia 11 No
Hypocarnitinemia 8 No
Metabolic acidosis 6 No
Hypercalciuria 15 No
Kidney stones 6 No
Prolonged QT 4 No
Hypoglycemia 12 No
Dehydration 14 No
Anemia 5 No
Obtundation 5 No
Renal tubular acidosis 1 Yes
Optic neuropathy 1 Yes
Infectious disease 2 Yes
Leukopenia 2 Yes
Dehydration + metabolic acidosis + vomiting 1 Yes
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have not found any signs or received any reports of long-term
health implications so far.
4. Discussion
In this collaborative study, 140 of the initial 216 patients
(65%) remained on the diet. Thirty-one patients (22%) became
seizure free and 48 children (34.5%) had a 75–99% decrease in
seizures. Thus, 56.5% of the patients attained a seizure control of
more than 75%. The best results were found in patients with
epilepsy with myoclonic-astatic seizures, Lennox–Gastaut syn-
drome, and West syndrome, including the symptomatic cases.
Good results were also found in patients with Dravet syndrome,
one of the most severe epilepsy syndromes. Good seizures
outcomes were also noted in patients with symptomatic focal
epilepsy secondary to malformations of cortical development
and tuberous sclerosis. Another important ﬁnding was that four
patients with FIRES and two patients with epileptic encephalop-
athy with continuous spikes and waves during slow sleep
(CSWSS) had a marked reduction in seizure frequency. Finally,
seizure control was signiﬁcantly improved in one patient with
epilepsy with myoclonic absences, one with Rett syndrome, and
another with subacute sclerosing panencephalitis.
Other studies conﬁrm our ﬁndings. The KD has been
successfully used in children with a variety of seizure types and
epileptic syndromes, including Lennox–Gastaut syndrome,2,20
infantile spasms,17,18,24 myoclonic-astatic epilepsy,20,23,25,34 Dra-
vet syndrome,21,23,26,35 Landau–Kleffner syndrome,36 tuberous
sclerosis,37,38 Rett syndrome,39–41 and – temporarily – subacute
sclerosing panencephalitis.42 Early diet intervention may lead to
better outcomes in children with Dravet syndrome, myoclonic-
astatic epilepsy, and Lennox–Gastaut syndrome.20–23 Recently, the
KD has proved to be effective in controlling status epilepticus in a
group of patients with FIRES, a devastating condition initiated by
prolonged Perisylvian refractory status epilepticus triggered by
fever of unknown cause. The KD may also be proposed as an
alternative treatment in other types of refractory status epilepticus
in pediatric patients.43 The efﬁcacy of the KD in patients with focal
seizures was similar to efﬁcacy in patients with generalized
seizures in uncontrolled trials.44,45 However, the KD was noteffective in patients with Lafora disease and did not stop disease
progression in these patients.46 Single reports mention the clinical
beneﬁts of the diet in metabolic diseases such as phosphofructo-
kinase deﬁciency,47 glycogenosis type V,48 and mitochondrial
respiratory chain complex disorders.30
It is interesting to note that a signiﬁcant number of our patients
who responded well to the KD additionally received topiramate.
This association may increase the risk of kidney stones, but may
also improve seizure control.49
Interictal epileptiform abnormalities improved in most of our
patients who had a seizure reduction of more than 75%. Similar
ﬁndings have been reported in the literature.15,33,50,51
The side effects of the KD are well described in the literature.49,52–
58 The actual incidence of side effects in patients treated with the
KD is difﬁcult to determine as few long-term prospective studies
have been conducted.
Of 216 patients treated with KD, seven (3.2%) discontinued the
diet due to adverse effects. Gastrointestinal manifestations were
the most frequent adverse effect. One patient presented a severe
copper deﬁcit, however, symptoms disappeared with copper
supplementation. The ﬁnding of copper deﬁciency in association
with KD has been previously published.52 The role of the KD in
producing copper deﬁciency is still not well known, but the copper
deﬁciency may be due to antioxidant deﬁciency in the bowel
secondary to KD.
The timing and method of KD discontinuation are tailored to the
patient’s response to the diet. Although current practice is to
continue with the diet for at least 3 months even if initially
ineffective, recent data suggest that the KD works rapidly with 75%
of children responding within 14 days.11 If a family opts to remain
on the KD for longer than 6 months even though the diet seems
ineffective, this decision should be supported.
In children with a greater than 50% seizure reduction, the KD is
typically discontinued after approximately 2 years, as the diet is
difﬁcult to maintain. This 2-year period is traditionally based on a
similar time period used for anticonvulsant drugs, which are often
discontinued after that time in children who become seizure free.
However, in children in whom seizure control is nearly complete (a
greater than 90% seizure reduction) and who have few side effects,
the diet has been reported to be useful for as long as 6–12 years.59
Children with GLUT-1 deﬁciency, pyruvate dehydrogenase deﬁ-
ciency, Dravet syndrome, symptomatic encephalopathies, cortical
dysplasia, or tuberous sclerosis complex may require longer KD
duration. The use of the KD was prolonged in patients with these
epilepsy syndromes described in this report. An EEG recording
should be obtained prior to discontinuing the KD, to identify risk
factors for seizure recurrence. In ﬁve patients, seizure frequency
improved after the diet was discontinued. These cases might
suggest that the ketogenic diet may have not only an anticonvul-
sant, but also an antiepileptogenic effect.60
Previous research has indicated that the risk of recurrence is
higher in patients with epileptiform EEGs, structural abnormalities
on neuroimaging, and tuberous sclerosis complex.61 The epilepsy
syndrome may also be of importance. In most patients with Dravet
syndrome who had a good response to KD seizures recurred after
diet discontinuation. In patients who had become seizure free and
in whom seizures recur after discontinuing the diet, seizure control
may be achieved again with either KD or anticonvulsants.61 A
recent study assessing the long-term safety and efﬁcacy of the KD
after the diet has been discontinued has shown that the majority of
patients were doing well both in terms of health and seizure
control.62
Future controlled studies with a long-term follow-up would be
necessary to better deﬁne the efﬁcacy, tolerability, duration of the
treatment, as well as the prognosis after discontinuing the diet
taking into account the epileptic syndromes.
R. Caraballo et al. / Seizure 20 (2011) 640–6456445. Conclusion
Our study corroborates that the KD is a good option in the
treatment of refractory epilepsy in terms of tolerability and
efﬁcacy. After discontinuing the diet, seizure recurrence occurred
in few patients. We have not observed any long-term health
implications so far.
In certain epileptic syndromes, such as epilepsy with myoclonic
astatic seizures, Dravet syndrome, cryptogenic Lennox–Gastaut
and West syndrome, the KD should be considered early in the
course of treatment.
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